SkinHealth Systems (SKIN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
22 Sep, 2026Opening remarks and agenda
Chairman Pedro Malha called the virtual meeting to order, introduced key management and board members, and outlined the agenda for the special meeting.
Confirmed proper notice, quorum, and lawful convening of the meeting for the business indicated in the notice and proxy statement.
Specific resolutions to be voted on
Proposal 1: Approve an amendment to the certificate of incorporation to effect a reverse stock split of Class A common stock at a ratio between 1-for-5 and 1-for-20, with the exact ratio to be set by the board.
Proposal 2: Approve adjournment of the meeting to a later date if necessary to solicit more votes or establish a quorum.
Both proposals require a majority of votes cast by stockholders present or represented by proxy.
The board recommended voting in favor of both proposals.
Q&A with stakeholders
Management opened the floor for questions related to the proposals, but no questions were submitted.
Latest events from SkinHealth Systems
- Shareholders to vote on a reverse stock split and possible meeting adjournment on Sept 22, 2026.SKIN
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SKIN
Proxy filing - Q2 2026 sales fell 7.8%, but margins and EBITDA improved amid ongoing market challenges.SKIN
Q2 2026 - Vote sought on a reverse stock split to maintain Nasdaq listing and increase share price.SKIN
Proxy filing - Director elections, auditor ratification, and executive pay were addressed; no questions submitted.SKIN
AGM 2026 - Adjusted EBITDA rose to $8.5M as sales fell and guidance was lowered amid market headwinds.SKIN
Q1 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.SKIN
Proxy filing - Margins and profitability improved in 2025, with stable outlook and growth expected in 2027.SKIN
Q4 2025 - Net sales dropped 22.9% as device sales lagged, prompting a downward revision to 2024 guidance.SKIN
Q2 2024